Pegylated liposomal doxorubicin (doxil): Reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2
Top Cited Papers
Open Access
- 1 August 2000
- journal article
- Published by Elsevier in Annals of Oncology
- Vol. 11 (8) , 1029-1034
- https://doi.org/10.1023/a:1008365716693
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Cardiotoxicity of Epirubicin/Paclitaxel–Containing Regimens: Role of Cardiac Risk FactorsJournal of Clinical Oncology, 1999
- Phase II Trial of Liposome-Encapsulated Doxorubicin, Cyclophosphamide, and Fluorouracil as First-Line Therapy in Patients With Metastatic Breast CancerJournal of Clinical Oncology, 1999
- The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi’s sarcoma patients treated with pegylated liposomal doxorubicinAnnals of Oncology, 1998
- Population pharmacokinetics and pharmacodynamics of pegylated-liposomal doxorubicin in patients with AIDS-related Kaposi's sarcomaClinical Pharmacology & Therapeutics, 1997
- Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study.Journal of Clinical Oncology, 1995
- Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies.Journal of Clinical Oncology, 1995
- Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy.Proceedings of the National Academy of Sciences, 1991
- Reduction of Doxorubicin Cardiotoxicity by Prolonged Continuous Intravenous InfusionAnnals of Internal Medicine, 1982
- Risk Factors for Doxorubicin-lnduced Congestive Heart FailureAnnals of Internal Medicine, 1979
- Adriamycin cardiotoxicityThe American Journal of Surgical Pathology, 1977